Maternal imbalance between pro-angiogenic and anti-angiogenic factors in HIV-infected women with pre-eclampsia

Cardiovascular Journal of Africa

Volumn 24, Issue 5, 2013, Pages 174-179

  Govender, Nalini ^a   Naicker, Thajasvarie ^a   Moodley, Jagidesa ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Anti angiogenic factors; HIV; Pre eclampsia; sFlt1

Indexed keywords

ENDOGLIN; PLACENTAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PREECLAMPSIA; PREGNANT WOMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADULT; ANTIGENS, CD; BIOLOGICAL MARKERS; BLOOD PRESSURE DETERMINATION; FEMALE; HIV INFECTIONS; HUMANS; MEMBRANE PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RECEPTORS, CELL SURFACE; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 84883396210     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: 10.5830/CVJA-2013-029     Document Type: Article

References (42)

1. Karumanchi SA, Bdolah Y. Hypoxia and sFlt-1 in preeclampsia: the 'chicken-and-egg' question. Endocrinology 2004; 145:4835-4837.
2. Levine RJ, Karamanchi SA. Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol 2005; 48: 372-386.
3. Steinberg G, Khankin EV, Karumanchi SA. Angiogenic factors and preeclampsia. Thromb Res 2009; 123: S93-S9.
4. Staff AC, Harsem NK, Braekke K, Hyer M, Hoover RN, Troisi R. Maternal, gestational and neonatal characteristics and maternal angiogenic factors in normotensive pregnancies. Eur J Obstet Gynecol Reprod Biol 2009; 143: 29-33.
5. Levine RJ, Thadhani R, Qian C, Lam C, Lim KH, Yu KF, et al. Urinary placental growth factor and risk of preeclampsia. J Am Med Assoc 2005; 293: 77-85.
6. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 365: 785-799.
7. Foidart JM, Schaaps JP, Chantraine F, Munaut C, Lorquet S. Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia - a step forward but not the definitive answer. J Reprod Immunol 2009; 88: 106-111.
8. Rana S, Lindheimer MD, Karumanchi A. Angiogenic proteins as markers for predicting preeclampsia. Exp Rev Obstet Gynaecol 2007; 2: 65-67.
9. Silasi M, Cohen B, Karumanchi SA, Rana S. Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia. Obstet Gynecol Clin North Am 2010; 37: 239-253.
10. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, et al. A longitudinal study of angiogenic (placental growth factor) and antiangiogenic (soluble endoglin and soluble VEGF receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small-for-gestational- age neonate. J Matern Fetal Neonatal Med 2008; 21: 9-23.
11. Moodley J. Maternal deaths due to hypertensive disorders in pregnancy. Best Prac Res Clin Obstet Gynaecol 2008; 22: 559-567.
12. Fourie C, Rooyen JV, Pieters M, Conradie K, Hoekstra T, Schutte A. Is HIV-1 infection associated with endothelial dysfunction in a population of African ancestry in South Africa? Cardiovasc J Afr 2011; 22: 134-140.
13. Mahmoud F, Omu A, Abul H, El-Rayes S, Haines D. Lymphocyte subpopulations in pregnancy complicated by hypertension. J Obstet Gynaecol 2003; 23: 20-26.
14. Wimalasundera RC, Larbalestier N, Smith JH, de Ruiter A, McG Thom SA, Hughes AD, et al. Pre-eclampsia,antiretro viral therapy, and immune reconstitution. Lancet 2002; 360: 1152-1154.
15. De Groot MR, Corporaal LJ, Cronje HS, Joubert G. HIV infection in critically ill obstetrical patients. Int J Gynaecol Obstet 2003; 81: 9-16.
16. Mattar R, Amed AM, Lindsey PC, Sass N, Daher S. Preeclampsia and HIV infection. Eur J Obstet Gynecol Reprod Biol 2004; 117: 240-241.
17. Lapaire O, Shennan A, Stepan H. The preeclampsia biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future application. Eur J Obstet Gynecol Reprod Biol 2010; 151: 122-129.
18. Suy A, Martinez E, Coll O, Lonca M, Palacio M, de Lazzari E, et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS 2006; 20: 59-66.
19. Frank KA, Buchmann EJ, Schackis RC. Does human immunodeficiency virus infection protect against preeclampsia-eclampsia? Obstet Gynecol 2004; 104: 238-242.
20. Eskild A, Vatten L. Do pregnancies with pre-eclampsia have smaller placentas? A population study of 317 688 pregnancies with and without growth restriction in the offspring. Br J Obstet Gynaecol 2010; 117: 1521-1526.
21. Levine RJ, Lam C, Qian C, Hu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. New Engl J Med 2006; 355: 992-1005.
22. Salahuddin S, Lee Y, Vadnais M, Sachs BP, Karumanchi S, Lim KH. Diagnostic utility of soluble fmslike tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol 2007; 197: 28.e1-e6.
23. Levine R, Karamanchi S. Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol 2005; 48: 372-386.
24. Ferrara N, Keyt B. Vascular endothelial growth factor: Basic biology and clinical implications. EXS J 1997; 79: 209-232.
25. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocrinol Rev 2004; 25: 581-611.
26. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrinol Rev 1997; 18: 4-25.
27. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658.
28. Lebrin F, Deckers M, Bertolino P, Dijke Pt. TGF-beta receptor function in the endothelium. Cardiovasc Res 2005; 65: 599-608.
29. Lim JH, Kim SY, SoYeonPark, Lee MH, Yang JH, Kim MY, et al. Soluble endoglin and transforming growth factor-β1in women who subsequently developed preeclampsia. Prenat Diagn 2009; 29(5): 471-476.
30. Lyall F. Priming and Remodelling of Human Placental Bed Spiral Arteries During Pregnancy - A Review. Placenta 2005; 26(Suppl A)
31. Trophoblast Res 19: S31-S6.
32. Luft FC. Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule. Nephrol Dial Transplant 2006; 21: 3052-3054.
33. Lopez-Novoa JM. Soluble endoglin is an accurate predictor and a pathogenic molecule in pre-eclampsia. Nephrol Dial Transplant 2007; 22(3): 712-714.
34. Maynard S, Epstein F, Karamanchi SA. Preeclampsia and angiogenic imbalance. Ann Rev Med 2008; 59: 61-78.
35. Maynard SE, Venkatesha S, Thadhani R, Karumanchi SA. Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res 2005; 57: 1R-7R.
36. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12: 642-649.
37. Staff AC, Braekke K, Harsem NK, Lyberg T, Holthe MR. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 2005; 122: 33-39.
38. Robinson CJ, Johnson DD, Chang EY, Armstrong DM, Wang W. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol 2006; 195: 255-259.
39. Simas TAM, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 2007; 197: 244e1-e8.
40. Vivo AD, Baviera G, Giordano D, Todarello G, Corrado F, D'Anna R. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol 2008; 87: 837-842.
41. Djurovic S, Schjetlein R, Wisloff F, Haugen G, Husby H, Berg K. Plasma concentrations of Lp (a) lipoprotein and TGF-beta 1 are altered in preeclampsia. Clin Genet 1997; 52: 371-376.
42. Huber A, Hefler L, Tempfer C, Zeisler H, Lebrecht A, Husslein P. Transforming growth factor-beta 1 serum levels in pregnancy and preeclampsia. Acta Obstet Gynecol Scand 2002; 81: 168-171.